BACKGROUND: Whether chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections contribute to the pathogenesis and⁄or course of chronic lymphocytic leukemia is unclear. OBJECTIVE: To document the prevalences of HBV and HCV infections in chronic lymphocytic leukemia patients, and to determine whether infected patients experience more aggressive disease than those without infection. METHODS: Patient sera were screened for antibodies to HBV core antigen and HCV (anti-HCV) using ELISA; both sera and peripheral blood lymphocytes were further tested (regardless of antibody results) for HBV-DNA and HCV-RNA using real-time polymerase chain reaction. Prognostic markers for chronic lymphocytic leukemia included Rai stage, IgVH mutational status, β2-microglobulin levels, Zap-70 and CD38 status. RESULTS: Fourteen of 222 (6.3%) chronic lymphocytic leukemia patients and two of 72 (2.8%) healthy controls tested positive for previous or ongoing HBV infection (OR 2.4 [95% CI 0.5 to 7.7]; P=0.25) while four of 222 (1.8%) chronic lymphocytic leukemia patients and one of 72 (1.4%) controls tested positive for HCV markers (OR 1.3 [95% CI 0.2 to 6.4]; P=0.81). The levels and distribution of the various indicators of aggressive chronic lymphocytic leukemia disease were similar among HBV- and HCV-infected and uninfected patients. Survival times were also similar. Occult HBV and HCV infection (HBV-DNA or HCV-RNA positive in the absence of diagnostic serological markers) were uncommon in chronic lymphocytic leukemia patients (0.5% and 1.8%, respectively). CONCLUSIONS: The results of the present study do not support the hypothesis that HBV or HCV infections play an important role in the pathogenesis or course of chronic lymphocytic leukemia.
BACKGROUND: Whether chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections contribute to the pathogenesis and⁄or course of chronic lymphocytic leukemia is unclear. OBJECTIVE: To document the prevalences of HBV and HCV infections in chronic lymphocytic leukemiapatients, and to determine whether infectedpatients experience more aggressive disease than those without infection. METHODS:Patient sera were screened for antibodies to HBV core antigen and HCV (anti-HCV) using ELISA; both sera and peripheral blood lymphocytes were further tested (regardless of antibody results) for HBV-DNA and HCV-RNA using real-time polymerase chain reaction. Prognostic markers for chronic lymphocytic leukemia included Rai stage, IgVH mutational status, β2-microglobulin levels, Zap-70 and CD38 status. RESULTS: Fourteen of 222 (6.3%) chronic lymphocytic leukemiapatients and two of 72 (2.8%) healthy controls tested positive for previous or ongoing HBV infection (OR 2.4 [95% CI 0.5 to 7.7]; P=0.25) while four of 222 (1.8%) chronic lymphocytic leukemiapatients and one of 72 (1.4%) controls tested positive for HCV markers (OR 1.3 [95% CI 0.2 to 6.4]; P=0.81). The levels and distribution of the various indicators of aggressive chronic lymphocytic leukemia disease were similar among HBV- and HCV-infected and uninfected patients. Survival times were also similar. Occult HBV and HCV infection (HBV-DNA or HCV-RNA positive in the absence of diagnostic serological markers) were uncommon in chronic lymphocytic leukemiapatients (0.5% and 1.8%, respectively). CONCLUSIONS: The results of the present study do not support the hypothesis that HBV or HCV infections play an important role in the pathogenesis or course of chronic lymphocytic leukemia.
Authors: Anatolii A Chumak; Irina V Abramenko; Nadia I Bilous; Irina A Filonenko; Oleksii V Kostin; Oksana Y Pleskach; Gleb V Pleskach; Nata Efremova; Julia Yanko Journal: J Immunotoxicol Date: 2010-06-03 Impact factor: 3.000
Authors: Violeta Molagic; Victoria Aramă; A Streinu Cercel; Nicoleta Irimescu; Ana Maria Vlădăreanu; M Olariu; S S Aramă; A Rafila; Camelia Dobrea; S Costoiu; Maria Mârza; D Oţelea; Simona Paraschiv; Dana Maxim; Mădălina Popa; H Bumbea; Cristina Ciufu; C Băicuş; Raluca Mihăilescu Journal: Rom J Intern Med Date: 2009
Authors: Diane F Jelinek; Renee C Tschumper; Gustavo A Stolovitzky; Stephen J Iturria; Yuhai Tu; Jorge Lepre; Nigam Shah; Neil E Kay Journal: Mol Cancer Res Date: 2003-03 Impact factor: 5.852
Authors: Jin-Hua Liang; Rui Gao; Jun-Cheng Dai; Robert Peter Gale; Wang Li; Lei Fan; Zhi-Bin Hu; Wei Xu; Jian-Yong Li Journal: J Cancer Res Clin Oncol Date: 2018-05-14 Impact factor: 4.553
Authors: Grécia C Pessoni; Tássia A Marinho; Megmar M Santos Carneiro; Regina M Martins; Caroline C Soares; Leandro N Silva; Marcia A Matos; Adriano M Arantes; Juliana A Teles; Nathalia C Santos; Sheila Araujo Teles Journal: Hematol Transfus Cell Ther Date: 2019-03-28